Actinium Pharmaceuticals (NYSE: ATNM) stock was up in pre-market trading on Monday after the company that develops targeted radiotherapies announced positive top-line results from Pivotal Phase 3 SIERRA Trial of Iomab-B. Iomab-B is used in patients with active relapsed or refractory acute myeloid leukemia (AML) - blood and bone marrow cancer. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was a randomized, multicenter, controlled study and was conducted in patients 55 years of age or older. These patients had active disease (relapsed or refractory AML).
https://www.tipranks.com/news/actinium-up-after-positive-topline-clinical-data?utm_source=advfn.com&utm_medium=referral